Trial Profile
A Multinational, Multicenter, Randomized, Parallel-Group Study Performed in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Laquinimod Over Placebo in a Double-blind Design and of a Reference Arm of Interferon β-1a (Avonex) in a Rater-blinded Design
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Apr 2022
Price :
$35
*
At a glance
- Drugs Laquinimod (Primary) ; Interferon beta-1a
- Indications Multiple sclerosis
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms BRAVO
- Sponsors Teva Pharmaceutical Industries
- 21 Apr 2016 Post-hoc analysis results (n=1990) (for this data was pooled from ALLEGRO and BRAVO trials) from this and ALLEGRO trials presented at the 68th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Results from ALLEGRO and BRAVO trials at 10 years presented at the 68th Annual Meeting of the American Academy of Neurology
- 21 Apr 2016 Results of a pooled analysis from ALLEGRO and BRAVO trials presented at the 68th Annual Meeting of the American Academy of Neurology